13 news items
Urogen Pharma Surges 9.7%: Is This an Indication of Further Gains?
RGNX
URGN
17 Jun 24
demonstrated an 82.3% 12-month duration of response by Kaplan-Meier estimate in patients who achieved complete response at three months following
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
ADBE
ARM
ECX
14 Jun 24
% 12-month duration of response in its Phase 3 ENVISION trial for UGN-102, achieving a 79.6% complete response rate at three months
UroGen Pharma Announces 82.3% 12-Month Duration Of Response In Phase 3 ENVISION Trial For UGN-102; Achieved 79.6% Complete Response Rate At Three Months
URGN
13 Jun 24
Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% (95% CI
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
URGN
13 Jun 24
Kaplan-Meier Estimate of Duration of Response
UroGen Pharma Announces Date For ENVISION Data, Long-Term Jelmyto Durability Data, To Be Discussed During Company Sponsored Virtual Event On June 13, 2024
URGN
13 May 24
12-month duration of response data from ENVISION study of UGN-102 to be discussed during company sponsored virtual event on June 13
gwqhxvv
URGN
6 May 24
New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months
UroGen
1tpxzbv9uqo7k6avrxtksd nwsnazor055i
URGN
6 May 24
response to the initial induction of this new treatment," said Adam Feldman, M.D., M.P.H., Urologic Oncologist in the Department of Urology
0ri197tnxs9shh5hmt0 5gu6
URGN
5 May 24
% recurrence-free survival rate at the 24-month mark among low-grade UTUC patients (n=53) exhibited a favorable response to the initial induction of this new
0ptreleki814 hhlja3piq
URGN
4 May 24
and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months
5c592neeafjppfunb7ilu8z9dpx76n8hd1f920usdb
URGN
4 May 24
% Complete Response Rate after JELMYTO Induction
25
yor9x2xv8nqf50dv504u4ffjkdfhrspf05qlpwbdl
URGN
17 Apr 24
Response
aubjqrztc1lkhvtue0l jfzy
URGN
15 Apr 24
the durability of response endpoint from the ENVISION Phase 3 study, UroGen anticipates submitting an NDA for UGN-102 in September 2024 and a potential FDA decision as early as the first quarter of 2025.
wv2gvmveolhgrrstpt7xjuut1zcqmn7n93 y9r5dezcjut4tlo36h0vcjg2
URGN
15 Apr 24
using a standard urinary catheter in an outpatient setting. Assuming positive findings from the durability of response endpoint from the ENVISION
- Prev
- 1
- Next